UBS Group’s SAB Biotherapeutics Warrant SABSW Stock Holding History

UBS Group’s Portfolio SABSW Stock Details SABSW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85	Buy	6,567 +2,381	+57%	+$45	﹤0.01%	10129
2026 Q1	$105	Sell	4,186 -2,000	-32%	-$69	﹤0.01%	10113
2025 Q4	$192	Sell	6,186 -17,228	-74%	-$524	﹤0.01%	10118
2025 Q3	$539	Buy	+23,414	New	+$782	﹤0.01%	9635
2025 Q1	–	Sell	-1,633	Closed	-$122	–	10655
2024 Q4	$122	Buy	+1,633	New	+$98	﹤0.01%	9630
2024 Q3	–	Sell	-56	Closed	-$3	–	9989
2024 Q2	$3	Buy	+56	New	+$2	﹤0.01%	9412
2024 Q1	–	Sell	-29,080	Closed	-$872	–	9925
2023 Q4	$872	Buy	+29,080	New	+$1.75K	﹤0.01%	8489
2023 Q3	–	Sell	-100	Closed	-$10	–	9893
2023 Q2	$10	Buy	+100	New	+$10	﹤0.01%	8736
2022 Q4	–	Sell	-5,606	Closed	–	–	11082
2022 Q3	$0	Buy	+5,606	New	+$669	﹤0.01%	10840
2022 Q1	–	Sell	-2,888	Closed	-$5K	–	10812
2021 Q4	$5K	Sell	2,888 -202	-7%	-$371	﹤0.01%	9415
2021 Q3	$3K	Buy	3,090 +939	+44%	+$671	﹤0.01%	8833
2021 Q2	$2K	Sell	2,151 -1,378	-39%	-$1K	﹤0.01%	8972
2021 Q1	$2K	Buy	+3,529	New	+$3.67K	﹤0.01%	8637

Other funds holding SABSW

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

GTS Securities Miami, Florida $4.75B AUM 41.97% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

UBS Group's SABSW Position: Q2 2026 in Review

UBS Group increased its SAB Biotherapeutics Warrant (SABSW) stake by 57% in Q2 2026, buying an estimated $45 and bringing the position to 6,567 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #10129.

UBS Group first reported a position in SABSW in Q1 2021 and has held it in 13 quarters since. The position peaked at $5K in Q4 2021. 8 funds tracked by Wall St. Rank hold SABSW as of Q2 2026.

UBS Group held 6,567 shares of SAB Biotherapeutics Warrant worth $85 as of Q2 2026.
UBS Group bought 2,381 SAB Biotherapeutics Warrant shares in Q2 2026, an estimated $45.
SAB Biotherapeutics Warrant made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #10129 holding.
UBS Group first reported a position in SAB Biotherapeutics Warrant in Q1 2021 and has held it in 13 quarters since.
UBS Group's SAB Biotherapeutics Warrant position peaked at $5K in Q4 2021.
8 funds tracked by Wall St. Rank held SAB Biotherapeutics Warrant as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.